Oxford BioDynamics' CRC Diagnostic Test Could Reduce Unnecessary Patient Follow-Ups
EpiSwitch NST Outperforms Competitors In Positive Predictive Values
Oxford BioDynamics' blood-based colorectal cancer diagnostic test EpiSwitch NST has shown high accuracy (81-85%) and positive predictive values (57-87%) for colorectal cancer and polyps. By reducing false positives, the test could minimize unnecessary follow-up procedures.
